Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
The hemolytic and cytolytic activities of Serratia marcescens phospholipase A (PhlA) depend on lysophospholipid production by PhlA.
PMID 20003541 · PMC2800117 · BMC microbiology · 2009 · 8 claims · 8 setups
S. marcescens possesses a hemolytic factor independent of ShlA, revealed because an shlAB deletion mutant loses contact hemolysis but retains hemolysis on blood agar plates.
-
Full-text index only
Activating mutations in ALK provide a therapeutic target in neuroblastoma.
PMID 18923525 · PMC2587486 · Nature · 2008 · 8 claims · 8 setups
Non-synonymous ALK kinase domain mutations occur in 8% of primary neuroblastomas, with F1174L being the most frequent
-
Full-text index only
Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line.
PMID 8382508 · PMC1968246 · British journal of cancer · 1993 · 8 claims · 5 setups
CEM/VP-1 is 15-fold more resistant to etoposide than parental CCRF-CEM cells
-
Full-text index only
A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes.
PMID 9449708 · PMC2212124 · The Journal of experimental medicine · 1998 · 8 claims · 8 setups
A gene, SART-1, encoding antigenic peptides recognized by HLA-A2601-restricted CTLs was identified from human squamous cell carcinoma cells.
-
Full-text index only
Finding the needle in the haystack: why high-throughput screening is good for your health.
PMID 12100740 · PMC138735 · Breast cancer research : BCR · 2002 · 8 claims · 8 setups
HTS is essential for finding lead compounds, especially for novel targets whose active-site structure is unknown